Anticancer Potential of Quercetin on Oral Squamous Cell Carcinoma: A Scoping Review and Molecular Docking

Abstract

Oral squamous cell carcinoma (OSCC) is a type of cancer that has a low survival rate and high recurrence and metastasis rates. To date, there is still no effective treatment for OSCC. Various types of cancer, including OSCC, have reported quercetin to act as an anticancer agent, but there is no clear research data on how it may affect OSCC. To determine the anticancer potential of quercetin in OSCC, we conducted a scoping review, and to determine the interaction of quercetin with one of the proteins that plays a role in carcinogenesis, namely, BCL-2, we conducted molecular docking. The scoping review process was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews. The scoping review was searched by collecting articles related to the research topic in Google Scholar, PubMed, ScienceDirect, Cochrane, and EBSCOhost databases. All of the literature records found during the search were imported into the Mendeley software to remove duplication. Nine studies were generated after the titles and abstracts were reviewed according to the inclusion and exclusion criteria. After the full-text screening, no studies were excluded, leaving nine publications determined to be eligible for inclusion in the scoping review. Quercetin showed effects on inhibiting cancer invasion, migration, proliferation, and many protein expressions, as well as increasing cell apoptosis. Molecular docking was done for quercetin and BCl-2 protein. Doxorubicin was utilized as a comparison ligand. The in silico study was utilized using AutoDock Vina, AutoDock Tools 1.5.6, Biovia Discovery Studio 2021, and PyMol. Molecular docking indicated quercetin has a strong binding affinity with BCl-2 protein (ΔG –7.2 kcal/mol). Both scoping review and molecular docking revealed that quercetin is a promising candidate for anticancer agent.

Keywords

quercetin - BCl-2 - oral cancer - scoping review - molecular docking

Publikationsverlauf

Artikel online veröffentlicht:
30. September 2024

• References

• 1 Badwelan M, Muaddi H, Ahmed A, Lee KT, Tran SD. Oral squamous cell carcinoma and concomitant primary tumors, what do we know? A review of the literature. Curr Oncol 2023; 30 (04) 3721-3734
• 2 Pavithra V, Kumari K, Haragannavar VC. et al. Possible role of Bcl-2 expression in metastatic and non metastatic oral squamous cell carcinoma. J Clin Diagn Res 2017; 11 (09) ZC51-ZC54
• 3 Cheng Y, Li S, Gao L, Zhi K, Ren W. The molecular basis and therapeutic aspects of cisplatin resistance in oral squamous cell carcinoma. Front Oncol 2021; 11: 761379
• 4 Bai J, Wu L, Wang X. et al. Roles of mitochondria in oral squamous cell carcinoma therapy: friend or foe?. Cancers (Basel) 2022; 14 (23) 5723
• 5 Zhang W, Li S, Li C, Li T, Huang Y. Remodeling tumor microenvironment with natural products to overcome drug resistance. Front Immunol 2022; 13: 1051998
• 6 Angellotti G, Di Prima G, Belfiore E, Campisi G, De Caro V. Chemopreventive and anticancer role of resveratrol against oral squamous cell carcinoma. Pharmaceutics 2023; 15 (01) 275
• 7 Zlotogorski A, Dayan A, Dayan D, Chaushu G, Salo T, Vered M. Nutraceuticals as new treatment approaches for oral cancer–I: curcumin. Oral Oncol 2013; 49 (03) 187-191
• 8 Sachdeva A, Dhawan D, Jain GK. et al. Novel strategies for the bioavailability augmentation and efficacy improvement of natural products in oral cancer. Cancers (Basel) 2022; 15 (01) 268
• 9 Butnariu M, Quispe C, Sharifi-Rad J. et al. Naturally-occurring bioactives in oral cancer: preclinical and clinical studies, bottlenecks and future directions. Front Biosci (Schol Ed) 2022; 14 (03) 24
• 10 Son HK, Kim D. Quercetin induces cell cycle arrest and apoptosis in YD10B and YD38 oral squamous cell carcinoma cells. Asian Pac J Cancer Prev 2023; 24 (01) 283-289
• 11 Garewal J, Garewal R, Sircar K. Expression of Bcl-2 and MIB-1 markers in oral squamous cell carcinoma (OSCC)- a comparative study. J Clin Diagn Res 2014; 8 (07) QC01-QC04
• 12 Tricco AC, Lillie E, Zarin W. et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 2018; 169 (07) 467-473
• 13 Peters MD, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid-Based Healthc 2015; 13 (03) 141-146
• 14 Moitessier N, Englebienne P, Lee D, Lawandi J, Corbeil CR. Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go. Br J Pharmacol 2008; 153 (Suppl 1, Suppl 1): S7-S26
• 15 Cosconati S, Forli S, Perryman AL, Harris R, Goodsell DS, Olson AJ. Virtual screening with AutoDock: theory and practice. Expert Opin Drug Discov 2010; 5 (06) 597-607
• 16 Tallei TE, Tumilaar SG, Niode NJ. et al. Potential of plant bioactive compounds as SARS-CoV-2 main protease (M^pro) and spike (S) glycoprotein inhibitors: a molecular docking study. Scientifica (Cairo) 2020; 2020: 6307457
• 17 Chan CY, Lien CH, Lee MF, Huang CY. Quercetin suppresses cellular migration and invasion in human head and neck squamous cell carcinoma (HNSCC). Biomedicine (Taipei) 2016; 6 (03) 15
• 18 Zhang W, Yin G, Dai J. et al. Chemoprevention by quercetin of oral squamous cell carcinoma by suppression of the NF-κB signaling pathway in DMBA-treated hamsters. Anticancer Res 2017; 37 (08) 4041-4049
• 19 Ma YS, Yao CN, Liu HC. et al. Quercetin induced apoptosis of human oral cancer SAS cells through mitochondria and endoplasmic reticulum mediated signaling pathways. Oncol Lett 2018; 15 (06) 9663-9672
• 20 Zhang C, Hao Y, Sun Y, Liu P. Quercetin suppresses the tumorigenesis of oral squamous cell carcinoma by regulating microRNA-22/WNT1/β-catenin axis. J Pharmacol Sci 2019; 140 (02) 128-136
• 21 Zhao J, Fang Z, Zha Z. et al. Quercetin inhibits cell viability, migration and invasion by regulating miR-16/HOXA10 axis in oral cancer. Eur J Pharmacol 2019; 847: 11-18
• 22 Kim SR, Lee EY, Kim DJ, Kim HJ, Park HR. Quercetin inhibits cell survival and metastatic ability via the EMT-mediated pathway in oral squamous cell carcinoma. Molecules 2020; 25 (03) 757
• 23 Chen L, Xia JS, Wu JH, Chen YG, Qiu CJ. Quercetin suppresses cell survival and invasion in oral squamous cell carcinoma via the miR-1254/CD36 cascade in vitro . Hum Exp Toxicol 2021; 40 (09) 1413-1421
• 24 Huang CF, Liu SH, Ho TJ. et al. Quercetin induces tongue squamous cell carcinoma cell apoptosis via the JNK activation-regulated ERK/GSK-3α/β-mediated mitochondria-dependent apoptotic signaling pathway. Oncol Lett 2022; 23 (03) 78
• 25 Salehi B, Lopez-Jornet P, Pons-Fuster López E. et al. Plant-derived bioactives in oral mucosal lesions: a key emphasis to curcumin, lycopene, chamomile, Aloe vera, green tea and coffee properties. Biomolecules 2019; 9 (03) 106
• 26 Asgharian P, Tazekand AP, Hosseini K. et al. Potential mechanisms of quercetin in cancer prevention: focus on cellular and molecular targets. Cancer Cell Int 2022; 22 (01) 257
• 27 Singh V, Singh R, Kujur PK, Singh RP. Combination of resveratrol and quercetin causes cell growth inhibition, DNA damage, cell cycle arrest, and apoptosis in oral cancer cells. Assay Drug Dev Technol 2020; 18 (05) 226-238
• 28 Li X, Guo S, Xiong XK. et al. Combination of quercetin and cisplatin enhances apoptosis in OSCC cells by downregulating xIAP through the NF-κB pathway. J Cancer 2019; 10 (19) 4509-4521
• 29 Cooper GM. The Cell: A Molecular Approach. Washington, DC: ASM Press; 1997: 12-15
• 30 Kaur G, Dufour JM. Cell lines: valuable tools or useless artifacts. Spermatogenesis 2012; 2 (01) 1-5
• 31 Alam M, Ali S, Mohammad T, Hasan GM, Yadav DK, Hassan MI. B cell lymphoma 2: a potential therapeutic target for cancer therapy. Int J Mol Sci 2021; 22 (19) 10442
• 32 Yunta MJR. Docking and ligand binding affinity: uses and pitfalls. Am J Model Optimizat 2016; 4 (03) 74-114
• 33 Wan S, Bhati AP, Zasada SJ, Coveney PV. Rapid, accurate, precise and reproducible ligand-protein binding free energy prediction. Interface Focus 2020; 10 (06) 20200007
• 34 Hata H, Phuoc Tran D, Marzouk Sobeh M, Kitao A. Binding free energy of protein/ligand complexes calculated using dissociation Parallel Cascade Selection Molecular Dynamics and Markov state model. Biophys Physicobiol 2021; 18: 305-316
• 35 Terefe EM, Ghosh A. Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of phytochemicals isolated from Croton dichogamus against the HIV-1 reverse transcriptase. Bioinform Biol Insights 2022 ;16:11779322221125605
• 36 Sahu VK, Khan AKR, Singh RK, Singh PP. Hydrophobic, polar and hydrogen bonding based drug-receptor interaction of tetrahydroimidazobenzodiazepinones. Am J Immunol 2008; 4 (03) 33-42
• 37 Young T, Abel R, Kim B, Berne BJ, Friesner RA. Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding. Proc Natl Acad Sci U S A 2007; 104 (03) 808-813
• 38 Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46 (1-3): 3-26
• 39 Karthik D. Prediction on binding affinity of some selected Coumarin and Anthraquinone derivates on cysteine rich C1 domain of kinase suppressor of RAS-1 (KSR-1) of MAPK signaling pathway. Journal of Computational Methods in Molecular Design. 2014; 4 (04) 131-139
• 40 Finn NA, Findley HW, Kemp ML. A switching mechanism in doxorubicin bioactivation can be exploited to control doxorubicin toxicity. PLOS Comput Biol 2011; 7 (09) e1002151
• 41 Maksimenko A, Dosio F, Mougin J. et al. A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity. Proc Natl Acad Sci U S A 2014; 111 (02) E217-E226
• 42 Wei L, Surma M, Gough G. et al. Dissecting the mechanisms of doxorubicin and oxidative stress-induced cytotoxicity: the involvement of actin cytoskeleton and ROCK1. PLoS One 2015; 10 (07) e0131763
• 43 Du L, Ma S, Wen X, Chai J, Zhou D. Oral squamous cell carcinoma cells are resistant to doxorubicin through upregulation of miR–221. Mol Med Rep 2017; 16 (03) 2659-2667
• 44 Juneja S, Chaitanya NB, Agarwal M. Immunohistochemical expression of Bcl-2 in oral epithelial dysplasia and oral squamous cell carcinoma. Indian J Cancer 2015; 52 (04) 505-510